List of Excipients in Branded Drug GOOD SENSE HAIR REGROWTH TREATMENT

« Back to Dashboard

Generic Drugs Containing GOOD SENSE HAIR REGROWTH TREATMENT

Company	Ingredient	NDC	Excipient
L Perrigo Company	minoxidil	0113-0294	ALCOHOL
L Perrigo Company	minoxidil	0113-0294	BUTANE
L Perrigo Company	minoxidil	0113-0294	BUTYLATED HYDROXYTOLUENE
L Perrigo Company	minoxidil	0113-0294	CETYL ALCOHOL
L Perrigo Company	minoxidil	0113-0294	CITRIC ACID MONOHYDRATE
L Perrigo Company	minoxidil	0113-0294	ISOBUTANE
L Perrigo Company	minoxidil	0113-0294	LACTIC ACID

What are the Most Frequently-Used Excipients in GOOD SENSE HAIR REGROWTH TREATMENT?

# Of NDCs	Excipient
5	ALCOHOL
2	BUTANE
3	BUTYLATED HYDROXYTOLUENE
3	CETYL ALCOHOL
3	CITRIC ACID MONOHYDRATE
3	ISOBUTANE
3	LACTIC ACID

Good Sense Hair Regrowth Treatment Excipient Strategy and Commercial Opportunities

Last updated: October 5, 2026

Good Sense Hair Regrowth Treatment is generally marketed in the United States as an over-the-counter topical minoxidil product. The core commercial opportunity is not a new active ingredient. It is a better topical delivery system that improves scalp tolerability, cosmetic acceptability, adherence, packaging, and channel economics while preserving minoxidil exposure and OTC compliance.

The standard Good Sense 5% topical solution uses minoxidil with alcohol, propylene glycol, and purified water. That composition is inexpensive and effective, but propylene glycol-related irritation, alcohol-related dryness, odor, residue, and application inconvenience create opportunities for differentiated products.

What is Good Sense Hair Regrowth Treatment?

Good Sense Hair Regrowth Treatment is a private-label topical minoxidil product used for androgenetic alopecia, commonly called male or female pattern hair loss.

Attribute	Typical Good Sense product profile
Active ingredient	Minoxidil
Common strength	5% topical solution
Dosage form	Topical liquid solution; other Good Sense or retailer variants may exist
Regulatory category	U.S. OTC drug
Common inactive ingredients	Alcohol, propylene glycol, purified water
Application site	Scalp
Primary indication	Treatment of hereditary hair loss
Commercial comparators	Rogaine, store-brand minoxidil, Kirkland Signature, Walgreens and CVS private labels
Primary differentiation lever	Vehicle, delivery system, tolerability, packaging, and price

The product should be analyzed at the individual SKU level because Good Sense products can differ by strength, dosage form, gender labeling, and package configuration. The excipient analysis below applies primarily to a conventional 5% minoxidil topical solution.

What excipients are used in Good Sense Hair Regrowth Treatment?

The conventional 5% minoxidil solution uses a simple hydroalcoholic vehicle.

Excipient	Primary function	Commercial benefit	Key risk
Ethanol or alcohol	Solvent and volatile carrier	Rapid drying and low manufacturing cost	Dryness, stinging, odor, flammability
Propylene glycol	Cosolvent and humectant	Improves minoxidil solubility and solution stability	Irritant or allergic contact dermatitis in some users
Purified water	Diluent	Adjusts vehicle composition and processing cost	Can affect solubility and preservation requirements
Minoxidil	Active ingredient	Promotes hair regrowth in indicated users	Limited solubility and possible local irritation

Minoxidil has limited water solubility. The alcohol-propylene glycol system keeps the active ingredient in solution at commercially useful concentrations. Removing propylene glycol without replacing its solubilizing function can cause precipitation, crystallization, dose nonuniformity, or reduced delivery to the scalp.

The formulation target is therefore not simply "propylene glycol-free." It is a stable, cosmetically acceptable vehicle that maintains minoxidil solubility through shelf life and application.

How strong is the current Good Sense excipient platform?

The conventional solution has a strong cost and manufacturing profile but limited differentiation.

Advantages

• Low excipient count
• Established raw-material supply
• Simple compounding and filling
• Familiar regulatory pathway
• Low unit cost
• Established consumer expectations
• Easy comparison with generic minoxidil products

Limitations

• Propylene glycol can cause scalp itching, redness, burning, and dermatitis.
• Alcohol can increase dryness and stinging.
• Liquid application can run down the scalp or contaminate hair.
• The product may leave a wet or oily feel.
• Repeated use can reduce consumer persistence.
• The solution format is less attractive for users who style their hair daily.
• Flammable alcohol requires appropriate storage, transportation, and packaging controls.

The commercial weakness is adherence. Minoxidil requires continued use, so a formulation that improves comfort and convenience can create more value than a modest reduction in manufacturing cost.

What excipient strategies could improve Good Sense?

1. Develop a propylene glycol-free liquid

A propylene glycol-free formulation is the most direct product-development opportunity. Candidate cosolvents include glycerin, polyethylene glycol, Transcutol-type solvents, or other pharmaceutically acceptable polyols and glycol ethers.

The principal development requirements are:

• Minoxidil solubility at the target concentration
• No crystallization during accelerated and long-term stability testing
• Acceptable scalp feel
• Controlled drying time
• Low irritation potential
• Compatibility with the container closure system
• Consistent delivered dose

Glycerin alone is unlikely to replicate the volatility and solubilization profile of alcohol-propylene glycol systems. A mixed-solvent approach may provide better balance but can increase tack, drying time, and hair residue.

2. Create a low-alcohol or alcohol-free solution

An alcohol-reduced product could address dryness and stinging. The formulation would require a different solvent architecture, potentially involving water, glycols, solubilizers, and surfactants.

The main technical risks are precipitation and poor cosmetic performance. An alcohol-free liquid may dry slowly and leave a noticeable film. That risk is commercially important because consumers often judge hair-loss products by feel and appearance rather than pharmacologic performance.

3. Use a foam dosage form

Foam is one of the strongest commercial alternatives to a conventional solution. A foam can reduce dripping, improve scalp targeting, and provide faster perceived drying.

Typical foam systems may contain fatty alcohols, surfactants, humectants, water, alcohol, and hydrocarbon propellants. The excipient strategy must address:

• Foam expansion and collapse time
• Uniform minoxidil distribution
• Propellant compatibility
• Valve and actuator performance
• Residual scalp film
• Container pressure and temperature stability
• Flammability labeling
• Package recycling and transport requirements

A propylene glycol-free foam has particular commercial value because branded minoxidil foam products have trained consumers to associate foam with lower mess and improved usability.

4. Introduce a scalp-conditioning system

Conditioning excipients can improve perceived tolerability, but the formulation should avoid unnecessary complexity. Possible components include low levels of panthenol, allantoin, glycerin, beta-glucan, or selected film-forming polymers.

These ingredients may support a "sensitive scalp" positioning, but they cannot be presented as treating scalp disease unless the product has a separate regulatory basis. They also can increase tack, alter drying, affect preservative performance, or interfere with minoxidil release.

A practical strategy is to use one or two conditioning ingredients supported by compatibility and irritation data rather than a broad cosmetic ingredient list.

5. Develop a waterless or anhydrous concentrate

An anhydrous system can simplify microbial-control strategy and improve stability. It may use alcohol, glycols, oils, or other nonaqueous solvents.

The opportunity is strongest for single-use applicators, precision droppers, or concentrated dose formats. The main disadvantages are flammability, scalp feel, potential residue, and the need to demonstrate reliable dosing across the product life cycle.

6. Improve the applicator rather than the formula

Packaging is an excipient-adjacent commercial lever. A precision applicator can improve the user experience without changing the active or vehicle.

Potential formats include:

• Metered-dose pump
• Narrow scalp applicator
• Comb or brush applicator
• Airless pump
• Unit-dose ampoule
• Applicator designed for use through dense hair

A metered pump can support more consistent application and reduce spillage. It may also permit a premium price without major reformulation risk.

What formulation patents protect minoxidil products?

Most conventional minoxidil solution products face limited composition-of-matter protection because minoxidil is an established generic active ingredient. The commercial protection landscape is more likely to involve formulation, foam, delivery-device, manufacturing, or method-of-use claims.

Relevant patent categories include:

Patent category	Potential claim focus	Commercial relevance
Foam formulation	Foam structure, solvent system, propellant, stability	May limit direct copying of branded foam designs
Propylene glycol-free vehicle	Solvent combinations and scalp tolerability	Useful for private-label differentiation
Nanoparticle or liposomal delivery	Particle composition and release profile	Higher development and regulatory burden
Microneedle or enhanced delivery	Device-assisted scalp delivery	Potentially higher efficacy, more complex regulation
Applicator technology	Metered delivery or scalp targeting	Can support packaging differentiation
Method of use	Treatment schedules or combination therapy	Scope may depend on claim wording and jurisdiction
Manufacturing method	Order of addition, crystallization control, process conditions	Can protect difficult-to-reproduce products

Patent clearance should be conducted against the exact proposed formulation and device. A general propylene glycol-free minoxidil solution is unlikely to be protected by a single broad, enforceable patent merely because it avoids propylene glycol. Risk depends on the particular solvent combination, dosage form, process, and claims in force.

When does Good Sense minoxidil lose exclusivity?

Good Sense minoxidil is an OTC generic-style product and does not have the exclusivity profile of a newly approved prescription drug.

Exclusivity issue	Assessment
New chemical entity exclusivity	Not applicable
Orphan-drug exclusivity	Not applicable
Biosimilar exclusivity	Not applicable
Prescription Orange Book exclusivity	Generally not applicable to the OTC product
OTC monograph protection	Depends on compliance with the applicable FDA monograph and labeling requirements
Composition-of-matter patent	Minoxidil is an established active ingredient
Formulation patent risk	Product-specific and potentially relevant
Generic launch barrier	Low for a compliant conventional solution, higher for differentiated delivery systems

FDA regulation of OTC minoxidil is principally governed by the OTC monograph framework and applicable labeling and manufacturing requirements. A manufacturer that follows the relevant monograph conditions can generally market a compliant product without relying on an NDA approval pathway. Products that depart materially from the monograph may require FDA review through an appropriate application or regulatory route. [1]

What is the Orange Book status of Good Sense Hair Regrowth Treatment?

Good Sense Hair Regrowth Treatment should not be treated like a conventional prescription drug with an Orange Book patent listing strategy. OTC monograph products are generally not commercialized through the same NDA and Paragraph IV framework used for prescription drugs.

The key legal questions are instead:

1. Does the formulation comply with the applicable OTC monograph?
2. Does the label contain permitted claims and directions?
3. Does the product satisfy current good manufacturing practice requirements?
4. Does the formulation infringe a third-party patent?
5. Does the packaging or advertising create an unapproved drug claim?

Are Paragraph IV challenges relevant to Good Sense minoxidil?

Paragraph IV litigation is usually not the central entry mechanism for a conventional OTC monograph minoxidil product. A company entering with a materially different formulation, device, or delivery technology may still face patent disputes, but the dispute would more likely concern formulation or device patents than a listed Orange Book patent covering the basic active ingredient.

A conventional 5% solution therefore has a relatively low legal entry barrier. The risk increases for:

• Propylene glycol-free formulations that copy a protected solvent system
• Foam products that replicate protected composition or process claims
• Specialized applicators
• Combination products
• Products making claims outside the OTC monograph
• Delivery technologies that increase scalp penetration

Which companies are competing with Good Sense?

Good Sense competes in a price-sensitive market with both branded and private-label products.

Competitor group	Examples	Competitive advantage
Branded minoxidil	Rogaine	Brand recognition and foam formats
Retail private label	Kirkland Signature, CVS, Walgreens and other store brands	Low price and broad availability
Online brands	Direct-to-consumer hair-loss companies	Subscription, telehealth, and bundled regimens
Prescription alternatives	Finasteride and topical finasteride products	Different mechanism and treatment positioning
Cosmetic scalp products	Caffeine, peptide, botanical, and cosmetic serums	Lower regulatory burden and lifestyle positioning
Device companies	Laser and light-based systems	Non-drug delivery and premium pricing

Good Sense has the strongest position where consumers prioritize price and basic access. It is weaker where consumers prioritize cosmetic feel, scalp comfort, packaging, digital engagement, and regimen support.

What commercial opportunities exist for Good Sense?

Premium tolerability SKU

A propylene glycol-free 5% solution could target users who discontinue conventional products because of itching or irritation. The product could command a higher price if supported by credible tolerability testing and a clearly differentiated package.

Foam expansion

A 5% foam provides the most recognizable premium format. It could compete with branded foam at a lower retail price while preserving private-label economics.

Sensitive-scalp line

A sensitive-scalp product could combine a simplified vehicle with carefully selected conditioning excipients. Claims should remain within OTC and cosmetic boundaries unless supported by a separate regulatory strategy.

Precision-dose packaging

A metered applicator could reduce waste and improve application consistency. This option has lower formulation risk than a new delivery system.

Subscription and adherence model

Minoxidil is a repeat-use product. Monthly refill packs, auto-replenishment, QR-linked instructions, and regimen reminders can increase retention. Packaging should support a clear one-month or three-month supply architecture.

Combination regimen

A broader hair-loss platform could pair minoxidil with cosmetic scalp care, shampoo, supplements, or prescription referral services. The commercial value is higher, but the company must separate drug claims from cosmetic and dietary-supplement claims.

What manufacturing and regulatory barriers apply?

A conventional minoxidil solution is relatively easy to manufacture, but the control strategy remains important.

Critical manufacturing controls include:

• Complete dissolution of minoxidil
• Control of alcohol and water ratios
• Prevention of crystallization
• Uniformity during bulk holding
• Accurate fill volume
• Container-closure compatibility
• Evaporation control
• Flammability controls
• Stability at relevant temperatures
• Microbial quality where water is present

Foam products add pressure-vessel, propellant, valve, and transportation requirements. Liposomal, nanoparticle, or microneedle products add substantially greater development, analytical, and regulatory complexity.

How does Good Sense compare with branded Rogaine?

Factor	Good Sense conventional solution	Branded Rogaine foam or solution
Price position	Value	Premium
Basic active	Minoxidil	Minoxidil
Vehicle differentiation	Usually limited	Greater format and brand differentiation
Consumer trust	Retailer-dependent	Strong branded recognition
Formulation opportunity	High for line extensions	High but constrained by brand architecture
Patent exposure	Usually low for basic solution	Higher for specific foam or delivery technologies
Margin strategy	Volume and low cost	Premium pricing and brand loyalty
Best growth lever	Improved vehicle and packaging	Product extensions and adherence programs

The active ingredient is not the primary differentiator. Vehicle design and consumer experience determine much of the competitive separation.

What is the recommended excipient strategy?

The strongest development sequence is:

1. Confirm the exact Good Sense SKU and current inactive-ingredient profile.
2. Establish a propylene glycol-free 5% solution as the lowest-risk formulation project.
3. Screen mixed-solvent systems for solubility, drying time, residue, and irritation.
4. Develop a foam only after identifying a stable and commercially acceptable minoxidil vehicle.
5. Test precision-dose packaging in parallel because it can create value without changing the formulation.
6. Conduct patent clearance on the final excipient combination, manufacturing process, foam architecture, and applicator.
7. Use human tolerability and consumer-use testing to support premium positioning.
8. Preserve the conventional low-cost solution as the value SKU.

Key Takeaways

• Good Sense Hair Regrowth Treatment is primarily a topical minoxidil OTC product.
• Its conventional alcohol-propylene glycol-water vehicle is inexpensive and established but has tolerability and cosmetic limitations.
• A propylene glycol-free 5% solution is the most practical formulation opportunity.
• Foam, precision applicators, and adherence-oriented packaging offer stronger commercial differentiation than minor excipient changes.
• Conventional OTC minoxidil has limited Orange Book, Paragraph IV, and exclusivity exposure.
• Formulation, foam, device, manufacturing, and delivery patents remain relevant for differentiated products.
• The best portfolio strategy is a low-cost solution, a premium tolerability SKU, and a foam or precision-dose extension.
• Revenue potential depends primarily on retail distribution, repeat use, product format, price architecture, and consumer retention rather than the active ingredient.

FAQs About Good Sense Hair Regrowth Treatment Excipients

Can propylene glycol be removed from Good Sense minoxidil?

Yes. Removing it requires a replacement solvent system that maintains minoxidil solubility, dose uniformity, stability, and acceptable scalp feel.

Is a minoxidil foam commercially better than a minoxidil solution?

A foam can support premium pricing because it dries faster, runs less, and may be easier to apply. Its manufacturing and packaging requirements are more complex.

Can Good Sense add botanical ingredients?

It can add cosmetic ingredients if they are compatible and the resulting claims remain within applicable drug, cosmetic, and labeling requirements. Botanical additions do not automatically improve minoxidil efficacy.

Does a new Good Sense excipient blend need a new FDA approval?

The answer depends on whether the product remains within the applicable OTC monograph and whether the formulation, labeling, dosage form, or claims depart from permitted conditions.

What is the lowest-risk commercial improvement?

A new applicator or a propylene glycol-free solution generally presents less development risk than nanoparticle delivery, microneedles, or a new combination drug.

References

1. U.S. Food and Drug Administration. (2024). Hair loss prevention and treatment drug products for over-the-counter human use: FDA regulatory framework and labeling requirements. FDA.

2. U.S. Food and Drug Administration. (2024). Drug facts label: Minoxidil topical solution, 5%. FDA/Drug label database.

3. DailyMed. (2024). Minoxidil topical solution, 5%: Drug label information. National Library of Medicine.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

5. U.S. Food and Drug Administration. (2024). Current good manufacturing practice requirements for finished pharmaceuticals. FDA.